Literature DB >> 21827632

Characterization of d-boroAla as a novel broad-spectrum antibacterial agent targeting d-Ala-d-Ala ligase.

Sandeep Putty1, Aman Rai, Darshan Jamindar, Paul Pagano, Cheryl L Quinn, Takehiko Mima, Herbert P Schweizer, William G Gutheil.   

Abstract

d-boroAla was previously characterized as an inhibitor of bacterial alanine racemase and d-Ala-d-Ala ligase enzymes (Biochemistry, 28, 1989, 3541). In this study, d-boroAla was identified and characterized as an antibacterial agent. d-boroAla has activity against both Gram-positive and Gram-negative organisms, with minimal inhibitory concentrations down to 8 μg / mL. A structure-function study on the alkyl side chain (NH(2) -CHR-B(OR')(2) ) revealed that d-boroAla is the most effective agent in a series including boroGly, d-boroHomoAla, and d-boroVal. l-boroAla was much less active, and N-acetylation completely abolished activity. An LC-MS / MS assay was used to demonstrate that d-boroAla exerts its antibacterial activity by inhibition of d-Ala-d-Ala ligase. d-boroAla is bactericidal at 1× minimal inhibitory concentration against Staphylococcus aureus and Bacillus subtilis, which each encode one copy of d-Ala-d-Ala ligase, and at 4× minimal inhibitory concentration against Escherichia coli and Salmonella enterica serovar Typhimurium, which each encode two copies of d-Ala-d-Ala ligase. d-boroAla demonstrated a frequency of resistance of 8 × 10(-8) at 4× minimal inhibitory concentration in S. aureus. These results demonstrate that d-boroAla has promising antibacterial activity and could serve as the lead agent in a new class of d-Ala-d-Ala ligase targeted antibacterial agents. This study also demonstrates d-boroAla as a possible probe for d-Ala-d-Ala ligase function.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21827632      PMCID: PMC3193593          DOI: 10.1111/j.1747-0285.2011.01210.x

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  24 in total

1.  Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori.

Authors:  B Björkholm; M Sjölund; P G Falk; O G Berg; L Engstrand; D I Andersson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

Review 2.  Antibacterials: are the new entries enough to deal with the emerging resistance problems?

Authors:  Christine T Barrett; John F Barrett
Journal:  Curr Opin Biotechnol       Date:  2003-12       Impact factor: 9.740

Review 3.  Meticillin resistant Staphylococcus aureus in the hospital.

Authors:  Jan Kluytmans; Marc Struelens
Journal:  BMJ       Date:  2009-02-12

4.  The bacteria fight back.

Authors:  Gary Taubes
Journal:  Science       Date:  2008-07-18       Impact factor: 47.728

5.  Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam.

Authors:  María E Pachón-Ibáñez; Felipe Fernández-Cuenca; Fernando Docobo-Pérez; Jerónimo Pachón; Alvaro Pascual
Journal:  J Antimicrob Chemother       Date:  2006-07-26       Impact factor: 5.790

6.  Crystal structure of Escherichia coli penicillin-binding protein 5 bound to a tripeptide boronic acid inhibitor: a role for Ser-110 in deacylation.

Authors:  George Nicola; Sridhar Peddi; Miglena Stefanova; Robert A Nicholas; William G Gutheil; Christopher Davies
Journal:  Biochemistry       Date:  2005-06-14       Impact factor: 3.162

7.  Cysteine proteases such as papain are not inhibited by substrate analogue peptidyl boronic acids.

Authors:  V Martichonok; J B Jones
Journal:  Bioorg Med Chem       Date:  1997-04       Impact factor: 3.641

8.  (1-Aminoethyl)boronic acid: a novel inhibitor for Bacillus stearothermophilus alanine racemase and Salmonella typhimurium D-alanine:D-alanine ligase (ADP-forming).

Authors:  K Duncan; W S Faraci; D S Matteson; C T Walsh
Journal:  Biochemistry       Date:  1989-04-18       Impact factor: 3.162

Review 9.  Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA).

Authors:  Peter C Appelbaum
Journal:  Int J Antimicrob Agents       Date:  2007-09-20       Impact factor: 5.283

10.  Invasive methicillin-resistant Staphylococcus aureus infections in the United States.

Authors:  R Monina Klevens; Melissa A Morrison; Joelle Nadle; Susan Petit; Ken Gershman; Susan Ray; Lee H Harrison; Ruth Lynfield; Ghinwa Dumyati; John M Townes; Allen S Craig; Elizabeth R Zell; Gregory E Fosheim; Linda K McDougal; Roberta B Carey; Scott K Fridkin
Journal:  JAMA       Date:  2007-10-17       Impact factor: 56.272

View more
  5 in total

Review 1.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

2.  LC-MS/MS-Based Separation and Quantification of Marfey's Reagent Derivatized Proteinogenic Amino Acid DL-Stereoisomers.

Authors:  Navid J Ayon; Amar Deep Sharma; William G Gutheil
Journal:  J Am Soc Mass Spectrom       Date:  2018-11-12       Impact factor: 3.109

3.  Antibiotic Effects on Methicillin-Resistant Staphylococcus aureus Cytoplasmic Peptidoglycan Intermediate Levels and Evidence for Potential Metabolite Level Regulatory Loops.

Authors:  Harika Vemula; Navid J Ayon; Alloch Burton; William G Gutheil
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

Review 4.  Amino Acid Based Antimicrobial Agents - Synthesis and Properties.

Authors:  Michał G Nowak; Andrzej S Skwarecki; Maria J Milewska
Journal:  ChemMedChem       Date:  2021-10-01       Impact factor: 3.540

5.  Burkholderia pseudomallei d-alanine-d-alanine ligase; detailed characterisation and assessment of a potential antibiotic drug target.

Authors:  Laura Díaz-Sáez; Leah S Torrie; Stuart P McElroy; David Gray; William N Hunter
Journal:  FEBS J       Date:  2019-07-16       Impact factor: 5.542

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.